Tag: safety

MONTREAL, June 30, 2025 (GLOBE NEWSWIRE) -- Dorel Industries Inc. (TSX: DII.B, DII.A) is providing a business update on its on-going operations as promised in its first quarter financial results press release issued on May 12, 2025.

The Company is announcing a strategic shift in its operations with a significant reduction in the size of its Home segment which is expected to return the segment to profitability in 2026. These changes will be facilitated by a reduced product line focusing on profitable categories and the elimination of the domestic manufacturing operations based in Cornwall, Ontario.

As described in the first quarter earnings release, Dorel Home initiated a new round of restructuring in the second quarter founded upon the reduction of the size of the organization and its ability to merge the sales, marketing and product development organization into the successful Cosco division. A limited number of high-performing Dorel Home import SKUs will be transferred to the Cosco portfolio, focused on categories and customers driving the highest contribution with the least added complexity.

Cosco has delivered consistent earnings and positive cash flow within the Home segment since 2010, including the period in which it was led by Troy Franks, current CEO of Dorel Home. The organization is built on a market-driven, customer centric approach that delivers innovative products with exceptional consumer value. For over 90 years, Cosco has been a trusted household brand known for reliable performance and quality.

CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is designed to enroll approximately 180 adults with PMN and expected to readout in 2029. PMN is a severe antibody-mediated disease of the kidney that is a leading cause of nephrotic syndrome and carries a significant risk of kidney failure.

KINGSTOWN, Saint Vincent and the Grenadines, June 30, 2025 (GLOBE NEWSWIRE) -- Amid a growing wave of phishing scams targeting the crypto industry, Millionero, a trusted spot and perpetual exchange, is taking a stand. The company is urging all users to stay vigilant and follow key safety measures as scammers impersonate brands, executives, and platforms with increasing sophistication.

SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), have until August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta and certain of Sarepta’s top executives with violations of the Securities Exchange Act of 1934.

— Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy —